Papillary thyroid cancer is the most common type of thyroid cancer, accounting for roughly 80% of all thyroid cancer diagnoses. It begins in the follicular cells of the thyroid, which are the cells responsible for producing a protein called thyroglobulin. The overall outlook is very favorable: most people diagnosed with papillary thyroid cancer are treated successfully, and it has one of the highest survival rates of any cancer.
Who Gets Papillary Thyroid Cancer
Thyroid cancer in general is more common in women than men and among people with a family history of thyroid disease. Based on recent data from the National Cancer Institute, the rate of new thyroid cancer cases is about 13.7 per 100,000 people per year, with the median age at diagnosis being 51. The most common age group at diagnosis is 55 to 64, though it can appear at any age, including in teenagers and young adults.
The most well-established risk factor is exposure to ionizing radiation, particularly during childhood. Research stemming from the 1986 Chornobyl nuclear accident confirmed that papillary thyroid cancer is the most common cancer to develop after radioactive fallout exposure. Those radiation-linked tumors tend to have distinct genomic changes (called fusion drivers) that differ from the mutations found in cases unrelated to radiation. In non-radiation cases, the two most common genetic drivers are BRAF and RAS mutations. A family history of thyroid cancer or other thyroid conditions also raises your risk.
Symptoms and How It’s Found
Most papillary thyroid cancers cause no symptoms early on. Many are discovered incidentally during imaging for something else entirely, or during a routine physical exam when a doctor feels a lump on your neck. As the cancer grows, it can cause:
- A lump (nodule) you can feel through the skin on your neck
- A feeling that close-fitting collars are becoming too tight
- Increasing hoarseness or other voice changes
- Difficulty swallowing
- Swollen lymph nodes in the neck
- Pain in the neck or throat
Because early symptoms are rare, many people first learn about a thyroid nodule during an ultrasound or CT scan done for an unrelated reason. The vast majority of thyroid nodules are benign, so finding one doesn’t mean you have cancer.
How It’s Diagnosed
When a suspicious thyroid nodule is found, the standard next step is a fine needle aspiration biopsy, usually performed under ultrasound guidance to make sure the needle is placed accurately within the nodule. A thin needle draws out a small sample of cells, which are then examined under a microscope.
Results are reported using a standardized six-tier system called the Bethesda System. About 70% of biopsies come back as benign, carrying less than a 3% chance of cancer. On the other end, a “malignant” result carries a 97 to 99% chance of being truly cancerous. Between those extremes are categories like “atypia of undetermined significance,” which carries a 5 to 15% cancer risk, and “suspicious for malignancy,” which carries a 60 to 75% risk. These middle categories often require additional testing or surgery to get a definitive answer.
Variants and Aggressiveness
Not all papillary thyroid cancers behave the same way. Pathologists classify them into several subtypes based on how the cells look under a microscope, and these subtypes carry different levels of concern.
The follicular variant is the most common subtype and generally behaves like standard papillary thyroid cancer. When it’s completely encapsulated and noninvasive, it’s actually reclassified as a non-cancerous entity (called NIFTP), which spares patients from unnecessary treatment and the psychological weight of a cancer diagnosis.
The tall cell variant is more aggressive. It tends to appear in patients over 50, grows larger, and is more likely to extend beyond the thyroid and spread to lymph nodes or distant sites. Some of these tumors also resist radioactive iodine treatment, which limits treatment options. The columnar cell variant is rare but similarly aggressive, particularly when it grows into surrounding tissue rather than staying contained within a capsule.
Staging and the Role of Age
Papillary thyroid cancer staging uses the standard TNM system, but with a feature unique to thyroid cancer: your age at diagnosis directly changes your stage. The current system sets the dividing line at age 55.
If you’re under 55, the staging is remarkably simplified. Without distant spread (to lungs or bones, for example), you’re Stage I regardless of how large the tumor is or whether it has spread to nearby lymph nodes. Even with distant spread, you’re only Stage II. This reflects the fact that younger patients have an excellent prognosis even with more advanced disease.
If you’re 55 or older, staging becomes more granular. A tumor 4 cm or smaller that’s confined to the thyroid with no lymph node involvement is Stage I. Lymph node spread or limited extension outside the thyroid moves you to Stage II. More extensive invasion into structures like the trachea or esophagus is Stage III, and the most advanced local invasion or any distant spread places you in Stage IV.
Treatment Options
Surgery is the primary treatment for papillary thyroid cancer. The two main options are removing half the thyroid (lobectomy) or the entire gland (total thyroidectomy).
For small, low-risk tumors under 1 cm that are confined to the thyroid, with no lymph node involvement and no history of head and neck radiation, a lobectomy alone is often sufficient. This approach carries fewer surgical complications, though about 5 to 10% of patients will eventually have a recurrence in the remaining thyroid tissue. Total thyroidectomy is more commonly chosen because papillary thyroid cancer frequently involves both sides of the gland, and removing everything eliminates that risk. Total thyroidectomy does mean you’ll need thyroid hormone replacement for life.
After surgery, some patients receive radioactive iodine therapy to destroy any remaining thyroid tissue and reduce the chance of recurrence. This is not routine for everyone. It’s most beneficial for higher-risk patients, and the decision depends on tumor size, whether the cancer invaded blood vessels or the thyroid capsule, and how many lymph nodes were involved. For tiny tumors under 1 cm (called microcarcinomas), the prognosis is already excellent with surgery alone, and radioactive iodine wouldn’t be expected to improve outcomes.
Recurrence and Long-Term Monitoring
Even after successful treatment, papillary thyroid cancer can come back, most commonly in the lymph nodes of the neck. The likelihood of recurrence depends heavily on what was found during the initial surgery. Patients who had no lymph node involvement at the time of surgery face about a 12% recurrence risk. Those with tiny, microscopic lymph node deposits have roughly a 24% risk. And patients who had larger, visible lymph node metastases face a recurrence risk close to 49%.
These numbers drive long-term follow-up plans. After treatment, you’ll typically have periodic neck ultrasounds and blood tests measuring thyroglobulin, a protein produced by thyroid cells. Rising thyroglobulin levels after thyroid removal can signal that thyroid cancer cells are still present or have returned. This monitoring continues for years, often indefinitely, though the frequency of check-ups decreases over time as the risk of late recurrence drops.
Even when papillary thyroid cancer does recur, it’s usually treatable. Recurrences in neck lymph nodes can often be addressed with additional surgery, and the cancer typically remains responsive to radioactive iodine. The slow-growing nature of most papillary thyroid cancers means that even recurrences rarely become life-threatening.